Ifosfamide is an alkylating agent and an analog of cyclophosphamide, used as a single agent or in combination with other agents to treat a wide variety of malignancies. These malignancies include:
Among all these cancers, the Food and Drug Administration (FDA) has approved the drug only for germline tumors of the testis. The indications for the use of ifosfamide include:
The FDA approved regimen is ifosfamide along with mesna at a dose of 1200g/m^2/day for five days and is repeated every three weeks or following count recovery. When using ifosfamide along with other chemotherapeutic drugs, mainly cisplatin, paclitaxel, or etoposide, there has been complete remission in about 21 to 26% of the population. Aggressive hydration (at least 2 liters oral or IV) is necessary during administration.
2. Soft tissue sarcomas (off label use):
Non-comparative studies have shown that the combination therapies with ifosfamide/mesna, when used as induction therapy, have demonstrated objective response rates around 40%.
3. Ewings Sarcoma (off label use):
Doses of ifosfamide vary based on the age group. Used alongside vincristine, etoposide, doxorubicin along with mesna in different regimens. Overall, survival is better with combination therapies.
Ifosfamide is dosed along with mesna at 1500 g/m2/day every three weeks. When used along with paclitaxel and cisplatin, the response rate was 18 to 45%.
5. Bladder Carcinoma: mainly advanced carcinoma (off label use):
6. Non-Hodgkins Lymphoma (off label Use):
Used in Burkitt lymphoma and diffuse large B cell lymphoma (DLBCL) as salvage therapy.
Used in relapsed or refractory cases in the ICE regimen (ifosfamide, carboplatin, and etoposide) along with mesna.
8. Small and Non-small-cell cancer:
When used as maintenance or consolidation have shown to have more benefit than the standard regimens.
9. Osteosarcoma (off label use):
Used in advanced stages, which are platinum-resistant. Many additional trials are underway. Response rates have been more than 40% when used as a combination.
Ifosfamide has off label use in the advanced stage of thymic cancer.
Ifosfamide belongs to the class of the oxazaphosphorine alkylating agents. It is an inactive compound in its parent form (pro-drug). It gets metabolized in the liver by CYP450 enzymes to active metabolites. These active metabolites (phosphoramide mustard derivatives and acrolein) bind to the DNA and inhibit DNA synthesis. The two mechanisms by which these metabolite acts are as follows. First, it causes cell damage by forming interstrand or intrastrand crosslinks, and second, it leads to apoptosis of the damaged cell. These active metabolites upregulate the reactive oxygen species (ROS), which results in irreparable DNA damage and cease the protein formation. When compared to other alkylating compounds, cyclophosphamide and ifosfamide have more anti-tumor activity as their derivatives, mainly, phosphoramide mustard derivatives and acrolein are cytotoxic rather than cytostatic. Filtration primarily occurs through the kidney, and the doses require adjustment according to renal function.
The primary mode of administration of the drug is through the intravenous (IV) route. The oral form had a bioavailability close to 100 percent but resulted in severe neurotoxicity, and since then, the administration has switched to the intravenous form.
For germ-cell testicluar cancer, the dosing regimen is 1.2 g/m^2 IV for the initial 5 days of a 21 day cycle.
Researchers discovered ifosfamide over two decades ago, but it was subject to dose limitations due to the development of hemorrhagic cystitis. Only after the availability of the thiol neuroprotective compound mesna was the drug was used more commonly to treat a wide range of malignancies. For this reason, the administration is almost always along with mesna. Mesna converts to dimesna in the plasma gets filtered at the level of kidneys where it switches back to mesna. At the urothelium, mesna combines with the active metabolites like acrolein (urotoxic) and forms a non-toxic compound, which then gets eliminated in the urine. Mesna administration can be either orally or IV. The half-life of mesna is around 0.4 hours. It is completely excreted in four hours if given IV and in eight hours if given orally.
Adverse effects are mainly dose-related. They can be described based on the systems. These include the gastrointestinal, dermatological, central nervous system, hematological, renal, endocrine, and cardiac:
There are very few known contraindications for the drug. The absolute contraindications are known hypersensitivity to the drug or its components and urinary tract outflow obstruction, while relative contraindications include myelosuppression and severe renal/hepatic involvement.
To understand the therapeutic index of the drug, one needs to know the pharmacokinetics and pharmacodynamics of the drug. Regarding the pharmacokinetics, the volume of distribution(Vd) of the drug is almost equal to the total body water when administered in the IV form. Vd varies with weight as well with age(elderly and pediatric). Vd increases with age and in obese individuals. The half-life of the drug after a single administration is four to seven hours. The total clearance of the drug is 3.6L/h. Usually, fractionation of the drug results in faster rates of elimination.
The most common dose administered is 1.2 gm/m^2/day, given very slowly over 30 minutes for five consecutive days. Complete blood count with differential, renal function, liver function, urine output, and urinalysis are necessary before each dose. Dosing repeats every three weeks or after hematological recovery. Drug levels can be measured in the urine by gas chromatography-mass spectrometry. The therapeutic drug monitoring takes place after assessing the pharmacokinetics of the first course of the drug followed by subsequent alterations in the dose as there is wide variability in the pharmacokinetics of ifosfamide.
Dosing needs to be adjusted in renal impairment as the drug undergoes renal elimination. Dose reduction is to 80% of the dose if creatinine clearance (CrCl) is 46 to 60 mL/minute. However, if CrCl is 31 to 45 mL/minute, administer 75% of the dose and with CrCl under 30 mL/minute, reduce to 70% of the regular dose. There is no requirement for dose adjustment with hepatic impairment, but caution is advisable. The drug requires adjustment according to weight.
The dose also needs to be adjusted according to the toxicity profile. Instances of severe leukopenia or thrombocytopenia require dosage reduction. In case more severe toxicity such as encephalopathy probably requires termination of therapy.
Most of the toxicities of ifosfamide are from its active metabolites. Acrolein plays a significant role in causing major renal and bladder related toxicities. As the kidneys filter these metabolites, they generate reactive oxygen species and nitrogen compounds, which results in damage to the renal as well as urothelial cells. The etiology behind neurotoxicity is similar to that of renal toxicity but is not fully understood. As with other anti-neoplastic drugs, ifosfamide is toxic to the bone marrow. Specific case reports have shown an association between ifosfamide and Fanconi syndrome. It results in cardiac toxicity and can cause pneumonitis. These toxicities include:
1. Hemorrhagic cystitis
The main adverse effects for years has been hemorrhagic cystitis. The theory behind it was that hepatic metabolism produced a product named acrolein, which was excreted by the kidneys and accumulated in the bladder. Through its apoptotic properties and production of multiple ROS as well as nitric oxide, it results in the release of numerous cytokines that cause ulceration of the bladder epithelium. As a result, it causes hemorrhagic cystitis. Mesna is a drug developed in 1983 to help with this adverse effect of ifosfamide. As described earlier, mesna combines with the urotoxic metabolites at the level of urothelium and results in a non-toxic product for excretion in the urine. It is always important to prevent the development of cystitis rather than treating it. The current treatment options available are continuous bladder irrigation, intravesicular infusion of ammonium potassium sulfate and formalin, and in some instances, cystectomy. Mesna should be administered before, during, and after ifosfamide along with aggressive hydration (at least 2 liters oral of the IV form) per day to prevent urotoxicity.
Central nervous system toxicity appears as encephalopathy with varying severity (confusion, hallucinations, drowsiness, coma). It presents in about 30% of the cases. The mechanism is unknown, and the symptoms occur with the administration of high doses of the drug either orally or intravenously but more with oral administration. Usually, the symptoms present within 2 to 96 hours after drug administration and are reversible within 48 to 72 hours following discontinuation of the drug. The mechanism of neurotoxicity is still unknown. Risk factors associated with the development of neurotoxicity include oral administration, previous chemotherapy with cisplatin, impaired renal and hepatic function, low albumin, and brain metastasis. Recent studies showed the utilization of methylene blue for both treatment and prophylaxis of ifosfamide-induced encephalopathy. Methylene blue helps in the reversal of symptoms within 24 hours of its administration. As prophylaxis, the severity of symptoms has reduced when compared to previous cycles and can restore the therapy with ifosfamide. The dosage of methylene blue is 50 mg orally in 5% glucose solution every four hours till recovery.
3. Hematological toxicity
Dose-limiting toxicity is myelosuppression. The blood counts reach a nadir in about 8 to 13 days of the treatment cycle. Recovery generally occurs around day 17 of the treatment cycle; this allows starting the next cycle in around three weeks after the first treatment. This effect is dose-related. The incidence of myelosuppression is low when fractionated doses are used rather than higher doses. At a dose of 1.2 gm/m^2/day for five days, the white cell count is below 3 x 109/L, and platelet count below 20000 occurs in 30% of cases.
Most commonly noted in children and is seen when co-administered with cisplatin. It can lead to Fanconi syndrome, in which there is impairment of proximal tubule function resulting in irreversible damage—clinically manifested as metabolic acidosis, polyuria, and renal phosphate wasting. Seen in about 5% of cases. Supplementation with vitamin D and phosphate is essential in the pediatric population affected. Etiology remains unclear.
4. Miscellaneous toxicities: There are reports of arrhythmias, heart failure, and pulmonary toxicity in the form of pneumonitis.
5. Malignancy of ureter and bladder: There have been case reports which demonstrated a case of multifocal urothelial carcinoma in a patient treated with ifosfamide many years ago.
For chemotherapy drug administration and monitoring, the role of nursing and pharmacy is very crucial. All healthcare providers need to collaborate as an interprofessional team to ensure optimal care and minimal adverse effects with any drug therapy, but even more so with a chemotherapeutic agent like ifosfamide. Nursing is helpful in closely watching the patient during and after drug administration, identifying the adverse reactions, and reporting them immediately. Oncology nurses have specialized training in the administration of chemotherapy. The role of pharmacists is crucial as they help formulate the dosing as well as monitor them for potential toxicity. Both nursing and pharmacists can provide patient counseling about the drug and what to expect following administration and as the cycles progress. For better outcomes, the plan requires detailed discussion among all the members involved in patient care like nurses, pharmacists, physicians as well as family to lower the mortality and morbidity. [Level 5]
|||Zalupski M,Baker LH, Ifosfamide. Journal of the National Cancer Institute. 1988 Jun 15; [PubMed PMID: 3286879]|
|||Dechant KL,Brogden RN,Pilkington T,Faulds D, Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep; [PubMed PMID: 1720382]|
|||Kondagunta GV,Bacik J,Donadio A,Bajorin D,Marion S,Sheinfeld J,Bosl GJ,Motzer RJ, Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20; [PubMed PMID: 16170162]|
|||Noujaim J,Constantinidou A,Messiou C,Thway K,Miah A,Benson C,Judson I,Jones RL, Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. American journal of clinical oncology. 2018 Feb; [PubMed PMID: 26523439]|
|||Wagner MJ,Gopalakrishnan V,Ravi V,Livingston JA,Conley AP,Araujo D,Somaiah N,Zarzour MA,Ratan R,Wang WL,Patel SR,Lazar A,Ludwig JA,Benjamin RS, Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. The oncologist. 2017 Oct; [PubMed PMID: 28710342]|
|||Scandurra G,Scibilia G,Banna GL,D'Agate G,Lipari H,Gieri S,Scollo P, Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. Journal of gynecologic oncology. 2015 Apr; [PubMed PMID: 25686397]|
|||Siefker-Radtke AO,Dinney CP,Shen Y,Williams DL,Kamat AM,Grossman HB,Millikan RE, A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 1; [PubMed PMID: 22914978]|
|||Fukunaga A,Hyuga M,Iwasaki M,Nakae Y,Kishimoto W,Maesako Y,Arima N, Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Journal of clinical and experimental hematopathology : JCEH. 2016; [PubMed PMID: 27334858]|
|||Zhou Y,Xu Y,Zhao J,Zhong W,Wang M, [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2015 Jun; [PubMed PMID: 26104891]|
|||Basaran M,Bavbek ES,Saglam S,Eralp L,Sakar B,Atalar AC,Bilgic B,Ozger H,Onat H, A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007; [PubMed PMID: 18185020]|
|||Shin W,Lee HJ,Yang SJ,Paik ES,Choi HJ,Kim TJ,Choi CH,Lee JW,Bae DS,Kim BG, Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics [PubMed PMID: 29780777]|
|||Grassin F,Paleiron N,André M,Caliandro R,Bretel JJ,Terrier P,Margery J,Le Chevalier T,Ruffié P, Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Jun; [PubMed PMID: 20521356]|
|||Ifosfamide-Induced Malignancy of Ureter and Bladder., Sannu A,Radha R,Mathews A,Padmakumari Mony R,Prahladan A,James FV,, Cureus, 2017 Aug 22 [PubMed PMID: 29062626]|
|||Voelcker G, Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anti-cancer drugs. 2018 Jan; [PubMed PMID: 29219879]|
|||Kerbusch T,de Kraker J,Keizer HJ,van Putten JW,Groen HJ,Jansen RL,Schellens JH,Beijnen JH, Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clinical pharmacokinetics. 2001 Jan; [PubMed PMID: 11236809]|
|||Klastersky J, Side effects of ifosfamide. Oncology. 2003; [PubMed PMID: 14586140]|
|||Dupuis LL,Boodhan S,Holdsworth M,Robinson PD,Hain R,Portwine C,O'Shaughnessy E,Sung L, Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatric blood [PubMed PMID: 23512831]|
|||Floyd JD,Nguyen DT,Lobins RL,Bashir Q,Doll DC,Perry MC, Cardiotoxicity of cancer therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Oct 20; [PubMed PMID: 16234530]|
|||Matz EL,Hsieh MH, Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017 Feb; [PubMed PMID: 27566144]|
|||Floyd J,Mirza I,Sachs B,Perry MC, Hepatotoxicity of chemotherapy. Seminars in oncology. 2006 Feb; [PubMed PMID: 16473644]|
|||Kerbusch T,Jeuken MJ,Derraz J,van Putten JW,Huitema AD,Beijnen JH, Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection. Therapeutic drug monitoring. 2000 Oct; [PubMed PMID: 11034269]|
|||Kintzel PE,Dorr RT, Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer treatment reviews. 1995 Jan; [PubMed PMID: 7859226]|
|||Griggs JJ,Mangu PB,Anderson H,Balaban EP,Dignam JJ,Hryniuk WM,Morrison VA,Pini TM,Runowicz CD,Rosner GL,Shayne M,Sparreboom A,Sucheston LE,Lyman GH, Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 May 1; [PubMed PMID: 22473167]|
|||Nicolao P,Giometto B, Neurological toxicity of ifosfamide. Oncology. 2003; [PubMed PMID: 14586141]|
|||Turner AR,Duong CD,Good DJ, Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2003 Oct; [PubMed PMID: 14570094]|
|||Morgan LR,Harrison EF,Hawke JE,Hunter HL,Costanzi JJ,Plotkin D,Tucker WG,Worrall PM, Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Seminars in oncology. 1982 Dec; [PubMed PMID: 7163813]|
|||Loebstein R,Koren G, Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998 Jun; [PubMed PMID: 9606250]|
|||Kandylis K,Vassilomanolakis M,Tsoussis S,Efremidis AP, Ifosfamide cardiotoxicity in humans. Cancer chemotherapy and pharmacology. 1989; [PubMed PMID: 2791194]|